Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European journal of cancer Année : 2021

Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

, , , , , , , , , , , , , , , , , , , (1, 2) , , , , ,
1
2
Julien Hadoux
  • Fonction : Auteur
Christina Kanaan
  • Fonction : Auteur
Alice Durand
  • Fonction : Auteur
Segolene Hescot
  • Fonction : Auteur
Vincent Hautefeuille
  • Fonction : Auteur
Guillaume Cadiot
  • Fonction : Auteur
Igor Tauveron
  • Fonction : Auteur
Sandrine Laboureau
  • Fonction : Auteur
Christine Do Cao
  • Fonction : Auteur
Thomas Walter
Caroline Petorin
  • Fonction : Auteur
Odile Blanchet
  • Fonction : Auteur
Arnaud Jannin
  • Fonction : Auteur
Celine Gu
  • Fonction : Auteur
Matthieu Faron
  • Fonction : Auteur
Emmanuelle Leteurtre
  • Fonction : Auteur
Marie -Christine Rousselet
  • Fonction : Auteur
Juliette J. Zakeyh
  • Fonction : Auteur
Aude Marchal
  • Fonction : Auteur
Clement Beaulaton
  • Fonction : Auteur
Valerie Hervieu
  • Fonction : Auteur
Michel Ducreux
  • Fonction : Auteur
Jean-Yves Scoazec
Eric Baudin

Résumé

Introduction and aim: : Neuroendocrine carcinomas (NECs) are aggressive malignant diseases. Platinum-etoposide (PE) combination is the standard first-line treatment, whatever the primary location. The NEC score and also retinoblastoma protein (Rb) status have been suggested to be predictive/prognostic factors in NEC. The primary objective of our multicentric retrospective study was to evaluate the prognostic relevance of the NEC score and Rb status, assessed by immunohistochemistry in PE-treated patients with metastatic NEC. Methods: Seven centres participated. The inclusion criteria were NEC, whatever the primary site, metastatic stage, first-line treatment with PE and tissue samples available. Rb status was determined centrally. Results: We report multicentric data from 185 metastatic patients (37% women, median age 63). There were 108 small-cell NECs (SCNECs, 58.4%), 50 large-cell NECs (LCNECs, 27%) and 27 not otherwise specified NECs (nosNECs, 14.6%). The primary sites were the thorax (37%), gastroenteropancreatic sites (38%), unknown (15%) and other (9%). The mean Ki-67 index was 76% (range 20-100). Rb status was interpretable in 122 cases. Rb expression was lost in 74% of the cases: 84% of SCNEC vs. 60% and 63% of LCNEC and nosNEC, respectively (p = 0.016). Objective response was seen in 70% of SCNEC, 45% of LCNEC and 48% of nosNEC (p < 0.001) and in 62% of Rb-negative tumours vs. 46% of Rb-positive tumours (p = 0.3). There was no difference in median progression-free survival or overall survival (OS) as per Rb status. Age, NEC score and response to chemotherapy were the main factors associated with OS in our cohort. Conclusion: In our series, Rb status had no prognostic impact in PE-treated metastatic patients with NEC, whereas age, NEC score and response to chemotherapy were the main factors associated with OS 2021 Elsevier Ltd. All rights reserved.
Fichier non déposé

Dates et versions

hal-03600262 , version 1 (07-03-2022)

Identifiants

Citer

Julien Hadoux, Christina Kanaan, Alice Durand, Segolene Hescot, Vincent Hautefeuille, et al.. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. European journal of cancer, 2021, 152, pp.100-115. ⟨10.1016/j.ejca.2021.04.030⟩. ⟨hal-03600262⟩

Collections

U-PICARDIE CHIMERE
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More